Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.98
USD
|
-1.00%
|
|
-0.50%
|
+230.00%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
26.01
|
19.83
|
81.03
|
21.03
|
17.29
|
70.25
|
-
|
Enterprise Value (EV)
1 |
26.01
|
19.83
|
81.03
|
21.03
|
17.29
|
70.25
|
70.25
|
P/E ratio
|
-2.4
x
|
-2
x
|
-5.99
x
|
-1.62
x
|
-1.94
x
|
-7.92
x
|
-3.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
54.3
x
|
142
x
|
157
x
|
-
|
-
|
-
|
EV / Revenue
|
-
|
54.3
x
|
142
x
|
157
x
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-8,923,801
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
12,154
|
18,362
|
28,784
|
28,810
|
28,814
|
35,481
|
-
|
Reference price
2 |
2.140
|
1.080
|
2.815
|
0.7300
|
0.6000
|
1.980
|
1.980
|
Announcement Date
|
3/26/20
|
3/18/21
|
3/8/22
|
3/31/23
|
3/8/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
0.365
|
0.571
|
0.134
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.45
|
-11.13
|
-12.22
|
-13.02
|
-8.891
|
-9.7
|
-28
|
Operating Margin
|
-
|
-3,050.14%
|
-2,139.58%
|
-9,714.18%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.8
|
-9.963
|
-12.25
|
-12.93
|
-8.86
|
-9.7
|
-28
|
Net income
1 |
-10.8
|
-9.983
|
-12.19
|
-13.07
|
-8.889
|
-9.7
|
-28
|
Net margin
|
-
|
-2,735.07%
|
-2,134.33%
|
-9,754.48%
|
-
|
-
|
-
|
EPS
2 |
-0.8900
|
-0.5400
|
-0.4700
|
-0.4500
|
-0.3100
|
-0.2500
|
-0.5400
|
Free Cash Flow
|
-
|
-
|
-9.08
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-1,590.19%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/18/21
|
3/8/22
|
3/31/23
|
3/8/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.14
|
0.165
|
0.068
|
0.044
|
0.008
|
0.014
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.093
|
-4.115
|
-3.835
|
-3.249
|
-2.865
|
-3.068
|
-2.212
|
-2.33
|
-2.386
|
-1.932
|
-2.1
|
-2.3
|
-2.5
|
-2.8
|
-
|
Operating Margin
|
-2,209.29%
|
-2,493.94%
|
-5,639.71%
|
-7,384.09%
|
-35,812.5%
|
-21,914.29%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.416
|
4.734
|
-3.791
|
-3.189
|
-2.873
|
-3.081
|
-2.19
|
-2.325
|
-2.35
|
-1.995
|
-2.1
|
-2.3
|
-2.5
|
-2.8
|
-
|
Net income
1 |
-2.461
|
4.916
|
-3.784
|
-3.185
|
-3.067
|
-3.035
|
-2.19
|
-2.325
|
-2.379
|
-1.995
|
-2.1
|
-2.3
|
-2.5
|
-2.8
|
-
|
Net margin
|
-1,757.86%
|
2,979.39%
|
-5,564.71%
|
-7,238.64%
|
-38,337.5%
|
-21,678.57%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0500
|
0.2100
|
-0.1300
|
-0.1100
|
-0.1100
|
-0.1000
|
-0.0800
|
-0.0800
|
-0.0800
|
-0.0700
|
-0.0600
|
-0.0600
|
-0.0600
|
-0.0600
|
-0.0800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/8/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/31/23
|
5/5/23
|
8/11/23
|
11/14/23
|
3/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-9.08
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.02
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
2.98%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/18/21
|
3/8/22
|
3/31/23
|
3/8/24
|
-
|
-
|
Last Close Price
1.98
USD Average target price
10
USD Spread / Average Target +405.05% Consensus |
1st Jan change
|
Capi.
|
---|
| +230.00% | 70.25M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|